Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Mexico: a systematic review
Publication: Journal of Comparative Effectiveness Research
Abstract
Aim: To investigate the data sources available in Mexico for real-world research. Materials & methods: A systematic literature review on PubMed, EMBASE and VHL using a combination of controlled vocabulary and keywords for the concepts of electronic health records, epidemiologic studies and Mexico was performed. Results: A total of 331 articles and 89 conference abstracts reporting real-world studies were identified. These included 320 data sources: 142 unique named databases, 172 unnamed databases from specified providers, and 26 electronic medical record datasets. The main data sources came from healthcare institutions (35%), followed by government agencies (26%). The most frequent database design corresponded to surveys (34%) and disease registries (20%). Most databases included cohort studies (43%), population-based (25%) and cross-sectional studies (18%). Specific diagnostic tests (28%), access (22%) and pharmacological treatment (21%) were the most common issues analyzed in databases at patient-level data. Neoplasms, cardiac disorders and infections/infestations were the most common therapeutic areas analyzed in databases. Conclusion: In Mexico, the use of databases has increased, driven by governmental and nongovernmental organisations and companies. However, further efforts are still needed to improve the quality and knowledge of real-world evidence.
Supplementary Material
File (supplementary material.docx)
- Download
- 385.71 KB
References
Papers of special note have been highlighted as: • of interest
1.
Novitzke JM. The significance of clinical trials. J. Vasc. Interv. Neurol. 1(1), 31 (2008).
2.
Eichler HG, Pignatti F, Schwarzer-Daum B et al. Randomized controlled trials versus real world evidence: neither magic nor myth. Clin. Pharmacol. Ther. 109(5), 1212–1218 (2021).
3.
Collins R, Bowman L, Landray M, Peto R. The magic of randomization versus the myth of real-world evidence. N. Engl. J. Med. 382(7), 674–678 (2020).
4.
Garrison LP, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health 10(5), 326–335 (2007).
• Although there are methodological challenges, real-world data are essential for making adequate reimbursement decisions.
5.
Zhang J, Symons J, Agapow P et al. Best practices in the real-world data life cycle. PLoS Digit. Health 1(1), e0000003 (2022).
6.
McGhan WF, Al M, Doshi JA, Kamae I, Marx SE, Rindress D. The ISPOR good practices for quality improvement of cost-effectiveness research task force report. Value Health 12(8), 1086–1099 (2009).
• To improve the quality of cost-effectiveness research, harmonization of guidelines and available instruments should be promoted.
7.
Lopes LC, Salas M, Osorio-de-Castro CGS et al. Data sources for drug utilization research in Latin American countries-a cross-national study: DASDUR-LATAM study. Pharmacoepidemiol. Drug Saf. 31(3), 343–352 (2022).
• Although multiple sources for drug utilization research are available in Latin American countries, the accessibility is limited in many places.
8.
Salas M, Lopes LC, Godman B et al. Challenges facing drug utilization research in the Latin American region. Pharmacoepidemiol. Drug Saf. 29(11), 1353–1363 (2020).
• In the Latin American countries there are relevant challenges regarding drug utilization research that are inherent to different healthcare and political systems.
9.
European Medicines Agency (EMA). Guideline on good pharmacovigilance practices (GVP) - Module VIII - Post-authorization safety studies (Rev. 3) EMA/813938/2011 Rev 3. First published 25 June 2012; last updated 12 October 2017. Available at: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf
10.
Stürmer T, Carey T, Poole C. ISPOR Health Policy Council proposed Good Research Practices for comparative effectiveness research: benefit or harm? Value Health 12(8), 1042–1043 (2009).
11.
Hunnicutt JN, Ulbricht CM, Chrysanthopoulou SA, Lapane KL. Probabilistic bias analysis in pharmacoepidemiology and comparative effectiveness research: a systematic review. Pharmacoepidemiol. Drug Saf. 25(12), 1343–1353 (2016).
12.
Donohue JM. A road map to rigor and relevance in pharmaceutical policy research. Milbank Q. 100(2), 341–344 (2022).
13.
Soumerai SB, Ross-Degnan D, Fortess EE, Abelson J. A critical analysis of studies of state drug reimbursement policies: research in need of discipline. Milbank Q. 71(2), 217–252 (1993).
14.
Khosla S, White R, Medina J et al. Real world evidence (RWE) – a disruptive innovation or the quiet evolution of medical evidence generation? F1000Research 7, 111 (2018).
15.
Deverka PA, Douglas MP, Phillips KA. Use of real-world evidence in US payer coverage decision-making for next-generation sequencing-based tests: challenges, opportunities, and potential solutions. Value Health 23(5), 540–550 (2020).
16.
Schad F, Thronicke A. Real-world evidence-current developments and perspectives. Int. J. Environ. Res. Public Health 19(16), 10159 (2022).
• Real-world evidence (RWE) has been included in various approval procedures of regulatory authorities, but there are important gaps and challenges to be resolved.
17.
Justo N, Espinoza MA, Ratto B et al. Real-world evidence in healthcare decision making: global trends and case studies from Latin America. Value Health 22(6), 739–749 (2019).
18.
Rodríguez-Tanta LY, Garavito Farro H, Freitas Leal L et al. Drug utilization research in Peru: is real-world data available? Front. Pharmacol. 13, 1047946 (2023).
19.
Franco JS, Vizcaya D. Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Colombia: a systematic review. Pharmacol. Res. Perspect. 8(5), e00661 (2020).
20.
Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339, b2700 (2009).
21.
Moher D, Liberati A, Tetzlaff J, Altman DG. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535 (2009).
22.
The European Centres for Pharmacoepidemiology and Pharmacovigilance. Guide on methodological standards in pharmacoepidemiology (Rev. 2). (2013). Available at: http://www.encepp.eu/standards_and_guidances
23.
Alcocer-Gamba MA, Martinez-Sanchez C, Verdejo-Paris J et al. Heart rate and use of beta-blockers in mexican stable outpatients with coronary artery disease. Arch. Cardiol. Mex. 85(4), 270–277 (2015).
24.
Leon-Jimenez C, Chiquete E, Cantu C et al. Citicoline for acute ischemic stroke in mexican hospitals: a retrospective postmarketing analysis. Methods Find. Exp. Clin. Pharmacol. 32(5), 325–330 (2010).
25.
Martinez-Sanchez C, Borrayo G, Carrillo J et al. Clinical management and hospital outcomes of acute coronary syndrome patients in Mexico: The Third National Registry of Acute Coronary Syndromes (RENASICA III). Arch. Cardiol. Mex. 86(3), 221–232 (2016).
26.
Oh S, Goto S, Accetta G et al. Vitamin K antagonist control in patients with atrial fibrillation in Asia compared with other regions of the world: real-world data from the GARFIELD-AF registry. Int. J. Cardiol. 223, 543–547 (2016).
27.
Parissis JT, Mantziari L, Kaldoglou N et al. Gender-related differences in patients with acute heart failure: management and predictors of in-hospital mortality. Int. J. Cardiol. 168(1), 185–189 (2013).
28.
Parissis JT, Rafouli-Stergiou P, Mebazaa A et al. Acute heart failure in patients with diabetes mellitus: clinical characteristics and predictors of in-hospital mortality. Int. J. Cardiol. 157(1), 108–113 (2012).
29.
Perdomo CD, Rodríguez ER, Carrasco Magallanes H et al. Impact of a community program for child malnutrition. Rev. Chil. Pediatr. 90(4), 411–421 (2019).
30.
Portocarrero-Ortiz LA, Vergara-Lopez A, Vidrio-Velazquez M et al. The Mexican Acromegaly Registry: clinical and biochemical characteristics at diagnosis and therapeutic outcomes. J. Clin. Endocrinol. Metab. 101(11), 3997–4004 (2016).
31.
Ruiz-Sandoval JL, Cantú C, Chiquete E et al. Aneurysmal subarachnoid hemorrhage in a Mexican multicenter registry of cerebrovascular disease: the RENAMEVASC study. J. Stroke Cerebrovasc. Dis. 18(1), 48–55 (2009).
32.
Ruiz-Sandoval JL, Chiquete E, Bañuelos-Becerra LJ et al. Cerebral venous thrombosis in a Mexican multicenter registry of acute cerebrovascular disease: the RENAMEVASC study. J. Stroke Cerebrovasc. Dis. 21(5), 395–400 (2012).
33.
Herrera AL, Góngora-Rivera F, Muruet W et al. Implementation of a stroke registry is associated with an improvement in stroke performance measures in a tertiary hospital in Mexico. J. Stroke Cerebrovasc. Dis. 24(4), 725–730 (2015).
34.
Jerjes-Sanchez C, Corbalan R, Barretto ACP et al. Stroke prevention in patients from Latin American countries with non-valvular atrial fibrillation: insights from the GARFIELD-AF registry. Clin. Cardiol. 42(5), 553–560 (2019).
35.
Juárez-Herrera U, Jerjes Sánchez C, González-Pacheco H et al. In-hospital outcome in patients with ST elevation myocardial infarction and right bundle branch block. A sub-study from RENASICA II, a national multicenter registry. Arch. Cardiol. Mex. 80(3), 154–158 (2010).
36.
Gonzalez-Aquines A, Cordero-Perez AC, Ramirez-Martinez LA et al. Onset-to-alarm time in patients with acute stroke: results from a Mexican population. Int. J. Stroke 13(7), NP19–NP21 (2018).
37.
Suwaidi JA. RENASICA II: a Mexican acute myocardial infarction registry that highlights the importance of regional registries. Glob. Cardiol. Sci. Pract. 2014(3), 232–234 (2014).
38.
Sánchez-Diaz CJ, García-Badillo E, Sánchez-Ramírez CJ et al. Clinical characteristics, process of care and outcomes among Mexican, Hispanic and non-Hispanic white patients presenting with non-ST elevation acute coronary syndromes: data from RENASICA and CRUSADE registries. Arch. Cardiol. Mex. 82(1), 14–21 (2012).
39.
Al-Naamani N, Espitia HG, Velazquez-Moreno H et al. Chronic thromboembolic pulmonary hypertension: experience from a single center in Mexico. Lung 194(2), 315–323 (2016).
40.
Antonio Gonzalez-Hermosillo J, Banos-Gonzalez MA, Guevara-Valdivia ME et al. Gender differences and management of stroke risk of nonvalvular atrial fibrillation in an upper middle-income country: insights from the CARMEN-AF registry. Int. J. Cardiol. Heart Vasc. 22, 117–122 (2019).
41.
Arauz A, Romano JG, Ruiz-Franco A et al. Differences in lipid profiles in two Hispanic ischemic stroke populations. Int. J. Stroke 9(4), 394–399 (2014).
42.
Bistola V, Simitsis P, Farmakis D et al. Association of mineralocorticoid receptor antagonist use and in-hospital outcomes in patients with acute heart failure. Clin. Res. Cardiol. 107(1), 76–86 (2018).
43.
Borrayo-Sánchez G, Rosas-Peralta M, Ramírez-Arias E et al. STEMI and NSTEMI: real-world study in Mexico (RENASCA). Arch. Med. Res. 49(8), 609–619 (2018).
44.
Chiang CE, Naditch-Brûlé L, Murin J et al. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circ. Arrhythm. Electrophysiol. 5(4), 632–639 (2012).
45.
Chiquete E, Ruiz-Sandoval JL, Murillo-Bonilla LM et al. Serum uric acid and outcome after acute ischemic stroke: PREMIER study. Cerebrovasc. Dis. 35(2), 168–174 (2013).
46.
Cohen M, Urban P, Christenson JT et al. Intra-aortic balloon counterpulsation in US and non-US centres: results of the Benchmark Registry. Eur. Heart J. 24(19), 1763–1770 (2003).
47.
Montalescot G, Sobhy M, Alam S et al. In-hospital management and outcome of Acute Coronary Syndromes (ACS) in developing countries: results of the ACCESS registry. Eur. Heart J. 30(Suppl. 1), 334–335 (2009).
48.
Parissis JT, Farmakis D, Ikonomidis I et al. Acute heart failure with preserved left ventricular ejection fraction in the ALARM-HF registry: predictors of in-hospital mortality. Eur. Heart J. 30(Suppl. 1), 838–839 (2009).
49.
Parissis JT, Fountoulaki K, Farmakis D et al. Body mass index and disease-modifying therapy in acute heart failure patients. Eur. Heart J. 34(Suppl. 1), 326 (2013).
50.
Rada FP, Suarez VP, Fernandez-Rangel E et al. Venous thromboembolic disease and thromboprophylaxis: experience in a medical-surgical ICU in Mexico. Crit. Care Med. 37(Suppl. 12), A377 (2009).
51.
Aguilera-Campos A, Asensio-Lafuente E, Fraga-Sastrías JM. [Analysis of the inclusion of police personnel on the out of hospital cardiac arrest emergency response]. Salud Publica Mex. 54(1), 60–67 (2012).
52.
Alcocer LA, Lozada O, Fanghänel G et al. Global cardiovascular risk stratification: comparison of the Framingham method with the SCORE method in the Mexican population. Cir. Cir. 79(2), 168–174 (2011).
53.
Arauz-Gongora A, Cantu C, Ruiz-Sandoval JL et al. Short-term prognosis of transient ischemic attacks. Mexican multicenter stroke registry. [Spanish]. Rev. Invest. Clin. 58(6), 530–539 (2006).
54.
Cantu-Brito C, Ruiz-Sandoval JL, Chiquete E et al. Risk factors, causes, and outcome in stroke types in Mexico. The RENAMEVASC Study. Rev. Mex. Neuroci. 12(5), 224–234 (2011).
55.
Escudero-Lourdes GV, Morales-Romero LV, Valverde-Ocaña C et al. [Cardiovascular risk in children from 6 to 15 years with exogenous obesity]. Rev. Med. Inst. Mex. Seguro Soc. 52(Suppl. 1), S58–S63 (2014).
56.
González-Hermosillo JA, Márquez MF, Ocampo-Peña S. [Design of an atrial fibrillation and embolic risk registry in Mexico: CARMEN-AF]. Arch. Cardiol. Mex. 87(1), 5–12 (2017).
57.
González-Pliego JA, Gudiño-Amezcua DA, Celis A et al. [Registry of myocardial infarction in a tertiary hospital of the Instituto Mexicano del Seguro Social]. Rev. Med. Inst. Mex. Seguro Soc. 52(4), 382–387 (2014).
58.
Iturralde-Torres P, Lara-Vaca S, Cordero-Cabra A et al. [Design of a multicenter registry to evaluate rhythm versus rate control in atrial fibrillation: Atrial Fibrillation Mexican Registry (ReMeFA)]. Arch. Cardiol. Mex. 81(1), 13–17 (2011).
59.
Lupi Herrera E. [National registry of acute ischemic coronary syndromes (RENASICA). Mexican Cardiology Society. The RENASICA Cooperative Group]. Arch. Cardiol. Mex. 72(Suppl. 2), S45–S64 (2022).
60.
Santa Cruz-Ruiz JM, Sahagún-Sánchez G, González-Cabello D et al. [Analysis of clinical, echocardiographic, microbiological and cytopathological characteristics of pericardial effusions in a tertiary hospital care]. Arch. Cardiol. Mex. 84(2), 86–91 (2014).
61.
Beltrán-Sánchez H, Drumond-Andrade FC, Riosmena F. Contribution of socioeconomic factors and health care access to the awareness and treatment of diabetes and hypertension among older Mexican adults. Salud Publica Mex. 57 (Suppl. 1), S6–S14 (2015).
62.
Doubova SV, Borja-Aburto VH, Guerra YGG et al. Loss of job-related right to healthcare is associated with reduced quality and clinical outcomes of diabetic patients in Mexico. Int. J. Qual. Health Care 30(4), 283–290 (2018).
63.
Kumar A, Wong R, Ottenbacher KJ et al. Prediabetes, undiagnosed diabetes, and diabetes among Mexican adults: findings from the Mexican Health and Aging Study. Ann. Epidemiol. 26(3), 163–170 (2016).
64.
Lloyd-Sherlock P, Beard J, Minicuci N et al. Hypertension among older adults in low and middle-income countries: prevalence, awareness and control. Int. J. Epidemiol. 43(1), 116–128 (2014).
65.
Lopez-Garcia YK, Colunga-Pedraza PR, Tarin-Arzaga L et al. Iron deficiency anemia referral to the hematologist. Real-world data from Mexico: the need for targeted teaching in primary care. Hematology 23(9), 658–663 (2018).
66.
Mendoza R, Tolentino-Mayo L, Hernández-Barrera L et al. Modifications in the consumption of energy, sugar, and saturated fat among the Mexican adult population: simulation of the effect when replacing processed foods that comply with a front of package labeling system. Nutrients 10(1), 101 (2018).
67.
Jaspersen-Gastelum J, Rodríguez JA, Espinosa de los Monteros FJ et al. Prostatic profile, premature ejaculation, erectile function and andropause in an at-risk Mexican population. Int. Urol. Nephrol. 41(2), 303–312 (2009).
68.
Pagan JA, Puig A. Differences in access to health care services between insured and uninsured adults with diabetes in Mexico. Diabetes Care 28(2), 425–426 (2005).
69.
Jones K, Ramirez J, Papadimitropoulos M et al. Resource utilization and costs associated with percutaneous coronary intervention when treating patients with acute coronary syndrome in the Mexican National Institute of Cardiology “Ignacio Chavez”. Value Health Reg. Issues 20, 136–141 (2019).
70.
Rosa-Diez G, Gonzalez-Bedat M, Ferreiro A et al. Burden of end-stage renal disease (ESRD) in Latin America. Clin. Nephrol. 86(13), 29–33 (2016).
71.
Rontoyanni VG, Avila JC, Kaul S et al. Association between obesity and serum 25(OH)D concentrations in older Mexican adults. Nutrients 9(2), 97 (2017).
72.
Gonzalez-Gonzalez C, Tysinger B, Goldman DP et al. Projecting diabetes prevalence among Mexicans aged 50 years and older: the Future Elderly Model-Mexico (FEM-Mexico). BMJ Open 7(10), e017330 (2017).
73.
Guerra G, Gutierrez-Calderon E, Salgado de Snyder N et al. Loss of job-related right to healthcare associated with employment turnover: challenges for the Mexican health system. BMC Health Serv. Res. 18(1), 457 (2018).
74.
Villalpando S, Pérez-Expósito AB, Shamah-Levy T et al. Distribution of anemia associated with micronutrient deficiencies other than iron in a probabilistic sample of Mexican children. Ann. Nutr. Metab. 50(6), 506–511 (2006).
75.
Seuring T, Goryakin Y, Suhrcke M. The impact of diabetes on employment in Mexico. Econ. Hum. Biol. 18, 85–100 (2015).
76.
Sosa-Rubi SG, Galarraga O, Lopez-Ridaura R. Diabetes treatment and control: the effect of public health insurance for the poor in Mexico. Bull. World Health Organ. 87(7), 512–519 (2009).
77.
Stoddard P, Handley MA, Vargas Bustamante A et al. The influence of indigenous status and community indigenous composition on obesity and diabetes among Mexican adults. Soc. Sci. Med. 73(11), 1635–1643 (2011).
78.
Sepúlveda J, Bustreo F, Tapia R et al. [Improvement of child survival in Mexico: the diagonal approach]. Salud Publica Mex. 49(Suppl. 1), S110–S125 (2007).
79.
Araiza-Garaygordobil D, Gonzalez-Pacheco H, Sierra-Fernandez C et al. Pre-hospital delay of patients with ST-elevation myocardial infarction in Mexico City. Arch. Cardiol. Mex. 89(2), 174–176 (2019).
80.
Ascencio-Montiel IJ. 10 years analysis of diabetes-related major lower extremity amputations in Mexico. Arch. Med. Res. 49(1), 58–64 (2018).
81.
Barquera S, Tovar-Guzmán V, Campos-Nonato I et al. Geography of diabetes mellitus mortality in Mexico: an epidemiologic transition analysis. Arch. Med. Res. 34(5), 407–414 (2003).
82.
Yeatman SE, Potter JE, Grossman DA. Over-the-Counter access, changing who guidelines, and contraindicated oral contraceptive use in Mexico. Stud. Fam. Plann. 37(3), 197–204 (2006).
83.
You Y, Doubova SV, Pinto-Masis D et al. Application of machine learning methodology to assess the performance of DIABETIMSS program for patients with Type 2 diabetes in family medicine clinics in Mexico. BMC Med. Inform. Decis. Mak. 19(1), 221 (2019).
84.
Cruz C, Campuzano-Rincón JC, Calleja-Castillo JM et al. Temporal trends in mortality from ischemic and hemorrhagic stroke in Mexico, 1980–2012. J. Stroke Cerebrovasc. Dis. 26(4), 725–732 (2017).
85.
Cuanalo de la Cerda HE, Ochoa Estrada E, Tuz Poot FR et al. Food intake and nutrition in children 1–4 years of age in Yucatan, Mexico. Ann. Hum. Biol. 41(1), 46–52 (2014).
86.
Cusumano AM, Di Gioia C, Hermida O et al. The Latin American Dialysis and Renal Transplantation Registry Annual Report 2002. Kidney Int. Suppl. 97, S46–S52 (2005).
87.
Doubova SV, Lamadrid-Figueroa H, Pérez-Cuevas R. Use of electronic health records to evaluate the quality of care for hypertensive patients in Mexican family medicine clinics. J. Hypertens. 31(8), 1714–1723 (2013).
88.
Aguilar-Frasco J, Arreola-Guerra J, Palau L et al. Evolution of GFR outcomes during the first year of transplant according to the kidney donor risk index transplantation in Mexico. The experience of a single center [abstract]. Am. J. Transplant. 15(Suppl. 3), C53 (2015).
89.
Chavez Palencia C, Arellano Gomez L. Eating habits of breakfast and lunch in Mexican children. Ann. Nutr. Metab. 71(Suppl. 2), 880–881 (2017).
90.
Galvan V, Jimenez GA, Moctezuma R et al. Cognitive function changes in patients with diabetes mellitus in Mexican population in ENASEM. J. Am. Geriatr. Soc. 66(Suppl. 2), S292 (2018).
91.
Godinez Olivas HF, Nader Kawachi JA, Cano Nigenda CV et al. Retrospective registry of cerebrovascular disease in a private third level referral academic hospital (Fundacion Clinica Medica Sur) in Mexico City. J. Neurol. Sci. 357(Suppl. 1), e379 (2015).
92.
Jimenez GA, Barragan A. Deficit-direct effect of insulin on cognitive impairment treatment. J. Am. Geriatr. Soc. 66 (Suppl. 2), S284 (2018).
93.
Jimenez P, Pastor V, Luna G. Estimating the cost of treating hypoglycemc events in the Mexican public health care system. Value Health 17(3), A129–A130 (2014).
94.
Lara MV, Rodriguez CM. Prevalence of cardiovascular risk factors in persons living with HIV at high activity antiretroviral therapy in Mexico City. J. Int. AIDS Soc. 18(2 Suppl. 3), 18–19 (2015).
95.
Magis-Rodriguez C, Casillas J, Alvarez-Wyssmann V et al. Cardiovascular risk assessment In HIV patients of an outpatient HIV clinic in Mexico City. J. Int. AIDS Soc. 16(2S1), 12 (2013).
96.
Oliva-Oropeza P, Quiroz Angulo ME, Marco Antonio AC. Cost-utility of sacral neuromodulation versus augmentation cystoplasty for treatment of refractory urge incontinence in Mexico. Value Health 14(7), A537 (2011).
97.
Panopoulou P, Garcia-Contreras F, Paladio-Hernandez JA et al. Economic impact of analogue insulin on health expenditure at the Mexican Institute of Social Security in 2012. An expenditure reduction proposal. Value Health 15(7), A497 (2012).
98.
Sanchez-Casillas JL, Ramirez-Lopez-De NMG. Cost-effectiveness of paricalcitol versus parathyroidectomy for secondary hyperparathyroidism to chronic kidney disease in Mexico. Value Health 16(7), A689 (2013).
99.
Noyola-Villalobos HF, Alberu-Gomez J, Gracida C et al. Fert results (results of the collaborative retrospective study in renal transplantation in Mexico. Transplantation 90, 926 (2010).
100.
Vieira D, Mehta S, Fernandez F et al. Synergy of artificial intelligence and single lead EKG to detect and localize STEMI. Eur. Heart J. 40(Suppl. 1), 1831 (2019).
101.
Arreola-Ornelas H, Rosado-Buzzo A, Garcia-Mollinedo M et al. Cost-effectiveness of tolterodine as treatment for overactive bladder (OAB) in adult mexican patients. Value Health 14(3), A76 (2011).
102.
Camacho ME, Saenz JL, McKey TA et al. Cardiovascular risk factors and lifestyles of older mexicans with cardiovascular events. J. Am. Geriatr. Soc. 62(Suppl. 1), S43 (2014).
103.
Aldrete-Velasco JA, Chiquete E, Rodriguez-Garcia JA et al. Chronic kidney disease mortality and its relation to diabetes in Mexico. Med. Interna Mex. 34(4), 536–550 (2018).
104.
Burboa-Noriega L, Burboa-Noriega J, Cristancho-Rojas C et al. Evaluation of the characteristics of aortic dissection by computed angio-tomography in the Mexican population. Arch. Cardiol. Mex. 88(5), 496–502 (2018).
105.
Calderón-Colmenero J, De-la-Llata M, Vizcaíno A et al. [Medical and surgical health care for congenital heart disease: a panoramic vision of the reality in Mexico. Inquiry 2009]. Rev. Invest. Clin. 63(4), 344–352 (2011).
106.
Chávez Valencia V, Orizaga de La Cruz C, Becerra Fuentes JG et al. [Epidemiology of glomerular disease in adults: a database review]. Gac. Med. Mex. 150(5), 403–408 (2014).
107.
Chavolla-Canal AJ, Gonzalez-Mercado MG, Ruiz-Larios OA. Prevalence of extensively drug-resistant bacteria isolated in urine cultures over an 8-year period at a secondary care hospital in Mexico. Rev. Mex. Urol. 76(4), 213–217 (2016).
108.
Sierra-Díaz E, Belmonte-Hernández MV, Villanueva-Pérez MA et al. [Non-traumatic spontaneous retroperitoneal bleeding: the effect of an early and accurate diagnosis]. Cir. Cir. 83(3), 206–210 (2015).
109.
Viramontes-Madrid JL, Jerjes-Sánchez C, Pelaez-Ballestas I et al. [Risk of drug interactions. Combinations of drugs associated with ventricular arrhythmias]. Rev. Invest. Clin. 54(3), 192–197 (2002).
110.
Gaytán-Hernández D, Díaz-Oviedo A, Gallegos-García V et al. [Future status of ischaemic heart disease in the state of San Luis Potosí: a predictive dynamic model]. Arch. Cardiol. Mex. 88(2), 140–147 (2018).
111.
Rizo Treviño S. Demographic and clinical characteristics, and adverse reactions of people with overweight and obesity consumers of orlistat, attended by a call center (2009–2017). Medwave 17(6), e7288 (2018).
112.
Murakami Y. Secondary data analysis of epidemiology in Asia. J. Epidemiol. 24(5), 345–346 (2014).
113.
Schneeweiss S. Learning from big health care data. N. Engl. J. Med. 370(23), 2161–2163 (2014).
114.
Chikwava F, Cordier R, Ferrante A, O'Donnell M, Speyer R, Parsons L. Research using population-based administration data integrated with longitudinal data in child protection settings: a systematic review. PLoS ONE 16(3), e0249088 (2021).
115.
Hinds A, Lix LM, Smith M, Quan H, Sanmartin C. Quality of administrative health databases in Canada: a scoping review. Can. J. Public Health 107(1), e56–e61 (2016).
116.
Cohen S, Gilutz H, Marelli AJ et al. Administrative health databases for addressing emerging issues in adults with CHD: a systematic review. Cardiol. Young 28(6), 844–853 (2018).
117.
Blayney DW. Transforming data from information to quality improvement: a panel discussion with electronic health record vendors. J. Oncol. Pract. 11(3), 174–175 (2015).
118.
Roberts MH, Ferguson GT. Real-world evidence: bridging gaps in evidence to guide payer decisions. Pharmacoecon. Open 5(1), 3–11 (2021).
119.
Csete J, Kamarulzaman A, Kazatchkine M et al. Public health and international drug policy. Lancet 387(10026), 1427–1480 (2016).
120.
Langlois EV, Becerril Montekio V, Young T, Song K, Alcalde-Rabanal J, Tran N. Enhancing evidence informed policymaking in complex health systems: lessons from multi-site collaborative approaches. Health Res. Policy Syst. 14, 20 (2016).
• A higher use of research in real-world policymaking is desirable, to better fit to the complex adaptive nature of health systems.
Information & Authors
Information
Published In
Copyright
© 2026 The authors. This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License
History
Received: 2 October 2025
Accepted: 26 January 2026
Published online: 5 March 2026
Keywords:
Topics
Authors
Metrics & Citations
Metrics
Article Usage
Article usage data only available from February 2023. Historical article usage data, showing the number of article downloads, is available upon request.
Citations
How to Cite
Availability of secondary healthcare data for conducting pharmacoepidemiology studies in Mexico: a systematic review. (2026) Journal of Comparative Effectiveness Research. DOI: 10.57264/cer-2025-0160
Export citation
Select the citation format you wish to export for this article or chapter.